Phase 1 Study of the Effect of Icosapent Ethyl on Warfarin Pharmacokinetic and Anticoagulation Parameters
Rene A. Braeckman • William G. Stirtan • Paresh N. Soni
Clin Drug Investig DOI 10.1007/s40261-014-0194-1
Background and Objective: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester approved to reduce triglyceride levels in patients with severe (C5.65 mmol/L) hypertriglyceridemia. EPA, the active metabolite of IPE, is mainly metabolized via β-oxidation, and studies suggest that omega-3 fatty acids such as EPA may have antithrombotic effects. The objective of this study was to evaluate the effect of IPE on the pharmacokinetic and anticoagulation pharmacodynamics of warfarin, a substrate of cytochrome P450 2C9-mediated metabolism.
Methods: Healthy adults received oral warfarin (25 mg) on day 1, oral IPE (4 g/day) on days 8 35, and coadministration on Day 29. Primary pharmacokinetic end points were area under the concentration-versus-time curve from zero to infinity (AUC 0–∞) and maximum plasma concentration (Cmax) for R-and S-warfarin; pharmacodynamic end points were area under the international normalized ratio (INR) effect-time curve after the warfarin dose (AUCINR) and maximum INR (INRmax).
Results: Twenty-five subjects completed the study. AUC0–∞ and Cmax ratios of geometric means for both R and S-warfarin following co-administration of warfarin with versus without IPE were within the 90 % confidence intervals of 0.80–1.25. AUCINR, INRmax, and ratios were also similar.
Conclusions: At steady-state concentrations, IPE at the approved dose of 4 g/day did not have an effect on the single dose pharmacokinetics or anticoagulation pharmacodynamics of 25-mg racemic warfarin in healthy adults. Co-administration of these drugs was safe and well-tolerated in this study of healthy adult subjects
Read Full Text (yellow highlights inside by Omega 3 Galilee)